- Home
- TNXP vs SSP Comparison
TNXP vs SSP Comparison
Compare TNXP & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- SSP
- Stock Information
- Founded
- TNXP 2007
- SSP 1878
- Country
- TNXP United States
- SSP United States
- Employees
- TNXP N/A
- SSP N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- SSP Broadcasting
- Sector
- TNXP Health Care
- SSP Industrials
- Exchange
- TNXP Nasdaq
- SSP Nasdaq
- Market Cap
- TNXP 213.7M
- SSP 205.8M
- IPO Year
- TNXP N/A
- SSP 1988
- Fundamental
- Price
- TNXP $18.12
- SSP $2.11
- Analyst Decision
- TNXP Buy
- SSP Buy
- Analyst Count
- TNXP 1
- SSP 2
- Target Price
- TNXP $70.00
- SSP $5.50
- AVG Volume (30 Days)
- TNXP 734.4K
- SSP 625.9K
- Earning Date
- TNXP 11-07-2025
- SSP 11-06-2025
- Dividend Yield
- TNXP N/A
- SSP N/A
- EPS Growth
- TNXP N/A
- SSP N/A
- EPS
- TNXP N/A
- SSP 0.48
- Revenue
- TNXP $9,831,000.00
- SSP $2,439,152,000.00
- Revenue This Year
- TNXP $14.79
- SSP N/A
- Revenue Next Year
- TNXP $933.49
- SSP $9.92
- P/E Ratio
- TNXP N/A
- SSP $4.41
- Revenue Growth
- TNXP N/A
- SSP 5.25
- 52 Week Low
- TNXP $6.76
- SSP $1.36
- 52 Week High
- TNXP $130.00
- SSP $4.17
- Technical
- Relative Strength Index (RSI)
- TNXP 34.78
- SSP 35.45
- Support Level
- TNXP $18.53
- SSP $2.26
- Resistance Level
- TNXP $18.96
- SSP $2.48
- Average True Range (ATR)
- TNXP 1.05
- SSP 0.12
- MACD
- TNXP 0.39
- SSP 0.00
- Stochastic Oscillator
- TNXP 24.31
- SSP 15.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.